Nasdaq warned biotechnology company MDRNA that it doesn't meet the minimum $10 million stock valuation requirement to be listed on the market.

Share story

Nasdaq warned biotechnology company MDRNA that it doesn’t meet the minimum $10 million stock valuation requirement to be listed on the market, the firm said Monday.

The Bothell company, formerly known as Nastech Pharmaceutical, said it would provide Nasdaq by Dec. 3 with its strategy on how to meet listing requirements.

“We are confident that Nasdaq will find our plan acceptable,” said MDRNA Chief Executive Michael French in a statement.

Ángel González: 206-515-5644 or agonzalez@seattletimes.com